{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020588","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.317074+00:00","generated_at":"2026-06-15T07:07:17.073253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track","bullets":["Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.","Net loss $31.7M ($0.43/share); R&D expense $25.6M, G&A $8.1M for Q1 2023.","TN-201 (gene therapy for HCM) received FDA Fast Track designation; Phase 1b to start Q3 2023.","Phase 1 dosing of TN-301 (HDAC6 inhibitor for HFpEF) complete; data expected H2 2023.","New Scientific Advisory Board members (Drs. Seidman, Marson) and Technical Advisory Board formed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020588","json":"https://secwatch.observer/filing/0000950170-23-020588.json","markdown":"https://secwatch.observer/filing/0000950170-23-020588.md","text":"https://secwatch.observer/filing/0000950170-23-020588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/0000950170-23-020588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/tnya-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:07:17.073253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46d3b2b72938da9a16914083aab01e6bef02712e","claim":"Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 10, 2023, Tenaya Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/0000950170-23-020588-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}